ImmunityBio, Inc. (NASDAQ:IBRX) is a biotechnology company focused on developing innovative immunotherapy treatments. Its flagship product, Anktiva, plays a crucial role in the company's growth, particularly in treating cancers unresponsive to traditional therapies. The company competes in a dynamic market with other biotech firms striving to advance cancer treatment options.
On February 23, 2026, H.C. Wainwright set a price target of $15 for IBRX, suggesting a potential upside of 54.56% from its current price of $9.71. This optimistic outlook aligns with the company's recent performance, as highlighted by a 16% surge in stock price following its fourth-quarter earnings announcement. The stock is currently priced at $9.72, reflecting an 11.67% increase, or $1.02 rise.
ImmunityBio's success is largely driven by Anktiva, which saw a remarkable 700% sales increase in 2025 and a 20% quarter-over-quarter growth in the fourth quarter. Despite a negative earnings per share of $0.06, the company has shown profitability improvement for three consecutive quarters. This progress has contributed to the stock quintupling in 2026, as highlighted by the company's positive developments.
The Cancer BioShield platform and Anktiva biologic product are key to ImmunityBio's strategy, stimulating natural killer cells, cytotoxic T cells, and memory T cells. These advancements help patients combat various cancers and diseases, with the majority of revenue coming from U.S. sales of Anktiva, particularly for bladder cancer cases unresponsive to Bacille Calmette-Guérin treatment.
IBRX's market capitalization stands at approximately $9.57 billion, with a trading volume of 73.67 million shares. The stock has fluctuated between $9.59 and $11 today, with a 52-week high of $11 and a low of $1.83. These figures reflect the company's growth potential and the market's confidence in its innovative cancer treatment solutions.
